Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of prostate cancer and ensuring that a prostatectomy with pelvic lymph node dissection is planned.

Eligibility criteria include being male, aged 18 years or older, and having unfavorable intermediate-risk, high-risk, or very high-risk prostate cancer as defined by specific guidelines.

Participants are required to understand and provide signed written informed consent before proceeding with the study activities.

The study involves the administration of 64Cu-PSMA I&T, a solution for injection, given through an intravenous injection. This is a diagnostic agent used to detect potential disease spread to lymph nodes.

After the administration of 64Cu-PSMA I&T, a PET/CT scan is performed. This scan helps in identifying the presence or absence of metastatic pelvic lymph nodes.

The scan results are compared to a histopathology reference standard to determine the accuracy of the diagnostic performance.

The sensitivity and specificity of the PET/CT scan are evaluated. Sensitivity refers to the ability to correctly identify patients with metastatic lymph nodes, while specificity refers to correctly identifying those without.

The results are interpreted by independent readers, and any treatment-emergent adverse events are monitored for up to 72 hours after the administration of the investigational product.